The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Keystone Symposia Immunometabolism, Metaflammation and Metabolic Disorders, (April 14-18, 2019) in Vancouver, British Columbia.

News detail

Return to all news & events

04/08/2019 Keystone Symposia Immunometabolism, Metaflammation and Metabolic Disorders, (April 14-18, 2019) in Vancouver, British Columbia.

Physiogenex will be present at the Keystone Symposia  Immunometabolism, Metaflammation and Metabolic Disorders meeting on April 15th, 2019 during the session poster 1 (7.30 pm- 10 pm)

Dr. François Briand, our Director of Research and Business Development, will present a poster dealing with our innovative NASH models:

ID 1014: “GLP-1 receptor agonists reduce liver inflammation in a 3-week Non Alcoholic SteatoHepatitis Mouse Model”.

Dr. Briand will be happy to discuss with you about your preclinical NASH project and how we can help you. Please Contact us to set-up an appointment.

About us

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.